Background: Leading-edge technology such as magnetic resonance imaging (MRI) or computed tomography (CT)\r\noften reveals mammographically and ultrasonographically occult lesions. MRI is a well-documented, effective tool to\r\nevaluate these lesions; however, the detection rate of targeted sonography varies for MRI detected lesions, and its\r\nsignificance is not well established in diagnostic strategy of MRI detected lesions. We assessed the utility of targeted\r\nsonography for multidetector-row CT (MDCT)- or MRI-detected lesions in practice.\r\nMethods: We retrospectively reviewed 695 patients with newly diagnosed breast cancer who were candidates for\r\nbreast conserving surgery and underwent MDCT or MRI in our hospital between January 2004 and March 2011.\r\nTargeted sonography was performed in all MDCT- or MRI-detected lesions followed by imaging-guided biopsy.\r\nPatient background, histopathology features and the sizes of the lesions were compared among benign, malignant\r\nand follow-up groups.\r\nResults: Of the 695 patients, 61 lesions in 56 patients were detected by MDCT or MRI. The MDCT- or MRI-detected\r\nlesions were identified by targeted sonography in 58 out of 61 lesions (95.1%). Patients with pathological diagnoses\r\nwere significantly older and more likely to be postmenopausal than the follow-up patients. Pathological diagnosis\r\nproved to be benign in 20 cases and malignant in 25. The remaining 16 lesions have been followed up.\r\nLesion size and shape were not significantly different among the benign, malignant and follow-up groups.\r\nConclusions: Approximately 95% of MDCT- or MRI-detected lesions were identified by targeted sonography, and\r\nnearly half of these lesions were pathologically proven malignancies in this study. Targeted sonography is a useful\r\nmodality for MDCT- or MRI-detected breast lesions.
Loading....